Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Children's Oncology Group
Seattle Children's Hospital
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Sun Yat-sen University
Children's Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seattle Children's Hospital
Seattle Children's Hospital
GlaxoSmithKline
Baylor College of Medicine
St. Jude Children's Research Hospital
Children's Hospital Medical Center, Cincinnati
Valent Technologies, LLC
Sun Yat-sen University
Instituto do Cancer do Estado de São Paulo
Shanghai Children's Medical Center
Eureka Therapeutics Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's National Research Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Emory University
Bayer
Masonic Cancer Center, University of Minnesota
New York Medical College
RenJi Hospital
Emory University
Baylor College of Medicine
Children's Oncology Group
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Children's Oncology Group
University of Birmingham
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Memorial Sloan Kettering Cancer Center
University of South Florida
National Cancer Institute (NCI)